AstraZeneca Pharma India to Sell Bengaluru Facility in Global Manufacturing Strategy Shift

17 Nov 2023 , 12:10 PM

AstraZeneca Pharma India, a subsidiary of AstraZeneca Plc, UK is set to sell its Bengaluru production facility as part of a global manufacturing and supply network review by its parent company.

The strategic move aligns with AstraZeneca’s commitment to advancing access to innovative medicines in India and leading in specialist disease areas. The company intends to exit the manufacturing site in Bangalore in due course, according to a regulatory filing.

The Bengaluru facility will be positioned for sale in a fully operational state, and AstraZeneca will search for a buyer who can also serve as a contract manufacturing organization (CMO) for its products, pending necessary statutory approvals.

AstraZeneca Pharma India emphasizes its awareness of the potential impact on employees and pledges its first responsibility to meet patient needs by ensuring an uninterrupted supply of medicines.

AstraZeneca Pharma India was established in 1979 and headquartered in Bengaluru. The Bengaluru facility is among nine global sites supporting clinical trial design, safety and efficacy monitoring, and other regulatory management throughout a product’s lifecycle.

For feedback and suggestions, write to us at [e-mail]